Cerus Corporation (NASDAQ: CERS) (Seite 17)
eröffnet am 25.05.17 16:58:43 von
neuester Beitrag 03.05.24 00:07:48 von
neuester Beitrag 03.05.24 00:07:48 von
Beiträge: 219
ID: 1.253.751
ID: 1.253.751
Aufrufe heute: 0
Gesamt: 12.837
Gesamt: 12.837
Aktive User: 0
ISIN: US1570851014 · WKN: 905249 · Symbol: CU2
1,7320
EUR
-0,74 %
-0,0130 EUR
Letzter Kurs 09.05.24 Tradegate
Neuigkeiten
02.05.24 · Business Wire (engl.)  |
18.04.24 · Business Wire (engl.) |
26.03.24 · Business Wire (engl.) |
19.03.24 · Business Wire (engl.) |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 8,2560 | +96,64 | |
| 17,780 | +47,43 | |
| 1,3300 | +30,51 | |
| 1,9800 | +26,11 | |
| 1,4700 | +23,01 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,7950 | -17,51 | |
| 9,9880 | -19,32 | |
| 0,7000 | -20,45 | |
| 2,9800 | -26,24 | |
| 3,2860 | -75,86 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 55.054.243 von occitania am 31.05.17 22:35:30Hm 
haste verkooft?
du bist so ruhig
Occi, ich denke du hast hier ne Perle entdeckt!
Kursziel für mich ----> 5 $
Cerus Corporation (NASDAQ: CERS)
haste verkooft?
du bist so ruhig
Occi, ich denke du hast hier ne Perle entdeckt!
Kursziel für mich ----> 5 $
Cerus Corporation (NASDAQ: CERS)
Antwort auf Beitrag Nr.: 55.053.127 von reaaalist am 31.05.17 19:55:59Salut reaaalist
Ich glaube...Es war nicht dumm...
Ich vermute ...Wir sehen bis freitags die 2,50 $
Nur m.Meinung
à bientôt
OC
Ich glaube...Es war nicht dumm...
Ich vermute ...Wir sehen bis freitags die 2,50 $
Nur m.Meinung
à bientôt
OC
Antwort auf Beitrag Nr.: 55.022.724 von occitania am 26.05.17 14:14:28Moin Occi
habe meine Posi heute ausgebaut!
War das dumm
habe meine Posi heute ausgebaut!
War das dumm
Antwort auf Beitrag Nr.: 55.049.191 von occitania am 31.05.17 12:47:05Salut
Als Orientierung
2nd Tabelle Suche Fenster CERS angeben --->Book Viewer
The Bats Exchanges
https://www.bats.com/us/equities/overview/
à bientôt
OC
Als Orientierung
2nd Tabelle Suche Fenster CERS angeben --->Book Viewer
The Bats Exchanges
https://www.bats.com/us/equities/overview/
à bientôt
OC
Trading Spotlight
Antwort auf Beitrag Nr.: 55.049.161 von occitania am 31.05.17 12:44:07Salut
Next Weeks Broker Price Targets For Cerus Corporation (CERS)
May 31, 2017 6:16 am
Quelle:http://www.fiscalstandard.com/2017/05/31/next-weeks-broker-p…
à bientôt
OC
Next Weeks Broker Price Targets For Cerus Corporation (CERS)
May 31, 2017 6:16 am
Quelle:http://www.fiscalstandard.com/2017/05/31/next-weeks-broker-p…
à bientôt
OC
Antwort auf Beitrag Nr.: 55.049.116 von occitania am 31.05.17 12:40:20Salut
Quelle:http://usacommercedaily.com/2017/05/30/cerus-corporation-cer…
Cerus Corporation (CERS) shares to see major resistance at $2.49
à bientôt
OC
Quelle:http://usacommercedaily.com/2017/05/30/cerus-corporation-cer…
Cerus Corporation (CERS) shares to see major resistance at $2.49
à bientôt
OC
Antwort auf Beitrag Nr.: 55.049.101 von occitania am 31.05.17 12:38:47Salut
Quelle:https://petroglobalnews24.com/2017-05-31-cantor-fitzgerald-…
à bientôt
OC
Quelle:https://petroglobalnews24.com/2017-05-31-cantor-fitzgerald-…
à bientôt
OC
Antwort auf Beitrag Nr.: 55.048.990 von occitania am 31.05.17 12:28:14Salut
May 31, 2017
Stocks: Cantor Fitzgerald Reiterates “$9.00” Price Target for Cerus Co. (CERS)
May 31, 2017 Kevin B. Atencio
Stocks: Cantor Fitzgerald Reiterates “$9.00” Price Target for Cerus Co. (CERS)
A number of other analysts have also commented on CERS. Zacks Investment Research lowered shares of Cerus from a “hold” rating to a “sell” rating in a research note on Thursday, January 5th. BTIG Research reiterated a “buy” rating and issued a $8.00 price objective on shares of Cerus in a research report on Friday, March 10th. FBR & Co set a $10.00 target price on Cerus and gave the company a “buy” rating in a research note on Wednesday, March 8th. Finally, Cowen and Company decreased their target price on Cerus from $9.50 to $7.00 and set an “outperform” rating on the stock in a report on Monday, April 17th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $8.40.
Cerus Co. (NASDAQ:CERS) received a $9.00 price objective from investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday, May 4th. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 298.23% from the stock’s current price.
Cerus (NASDAQ:CERS) opened at 2.26 on Thursday. The company’s 50-day moving average is $3.73 and its 200 day moving average is $4.36. Cerus has a one year low of $2.19 and a one year high of $7.64. The stock’s market capitalization is $234.90 million.
In other news, insider William Mariner Greenman sold 8,786 shares of Cerus stock in a transaction on Wednesday, March 15th. The shares were sold at an average price of $4.21, for a total transaction of $36,989.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last three months, insiders have sold 14,695 shares of company stock worth $61,652. 6.60% of the stock is currently owned by corporate insiders. Several hedge funds have recently bought and sold shares of CERS. ARK Investment Management LLC acquired a new stake in Cerus during the fourth quarter worth about $2,879,000. Bayesian Capital Management LP purchased a new position in Cerus during the fourth quarter worth approximately $202,000. J. Goldman & Co LP bought a new stake in Cerus during the fourth quarter valued at about $224,000. Trexquant Investment LP acquired a new stake in Cerus during the fourth quarter valued at $434,000. Finally, Baird Financial Group Inc. raised its position in Cerus by 7.8% in the fourth quarter. Baird Financial Group Inc. now owns 202,000 shares of the biotechnology company’s stock valued at $879,000 after buying an additional 14,628 shares in the last quarter. 68.91% of the stock is owned by institutional investors and hedge funds.
About Cerus Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
à bientôt
OC
May 31, 2017
Stocks: Cantor Fitzgerald Reiterates “$9.00” Price Target for Cerus Co. (CERS)
May 31, 2017 Kevin B. Atencio
Stocks: Cantor Fitzgerald Reiterates “$9.00” Price Target for Cerus Co. (CERS)
A number of other analysts have also commented on CERS. Zacks Investment Research lowered shares of Cerus from a “hold” rating to a “sell” rating in a research note on Thursday, January 5th. BTIG Research reiterated a “buy” rating and issued a $8.00 price objective on shares of Cerus in a research report on Friday, March 10th. FBR & Co set a $10.00 target price on Cerus and gave the company a “buy” rating in a research note on Wednesday, March 8th. Finally, Cowen and Company decreased their target price on Cerus from $9.50 to $7.00 and set an “outperform” rating on the stock in a report on Monday, April 17th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $8.40.
Cerus Co. (NASDAQ:CERS) received a $9.00 price objective from investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday, May 4th. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 298.23% from the stock’s current price.
Cerus (NASDAQ:CERS) opened at 2.26 on Thursday. The company’s 50-day moving average is $3.73 and its 200 day moving average is $4.36. Cerus has a one year low of $2.19 and a one year high of $7.64. The stock’s market capitalization is $234.90 million.
In other news, insider William Mariner Greenman sold 8,786 shares of Cerus stock in a transaction on Wednesday, March 15th. The shares were sold at an average price of $4.21, for a total transaction of $36,989.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last three months, insiders have sold 14,695 shares of company stock worth $61,652. 6.60% of the stock is currently owned by corporate insiders. Several hedge funds have recently bought and sold shares of CERS. ARK Investment Management LLC acquired a new stake in Cerus during the fourth quarter worth about $2,879,000. Bayesian Capital Management LP purchased a new position in Cerus during the fourth quarter worth approximately $202,000. J. Goldman & Co LP bought a new stake in Cerus during the fourth quarter valued at about $224,000. Trexquant Investment LP acquired a new stake in Cerus during the fourth quarter valued at $434,000. Finally, Baird Financial Group Inc. raised its position in Cerus by 7.8% in the fourth quarter. Baird Financial Group Inc. now owns 202,000 shares of the biotechnology company’s stock valued at $879,000 after buying an additional 14,628 shares in the last quarter. 68.91% of the stock is owned by institutional investors and hedge funds.
About Cerus Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
à bientôt
OC
Antwort auf Beitrag Nr.: 55.031.083 von occitania am 28.05.17 15:01:32Salut
Habe gestern nachgeladen
Investor’s Watch List: Cerus Corporation (CERS)
By
Leticia Jefferson -
May 30, 2017
http://theriponadvance.com/investors-watch-list-cerus-corpor…
à bientôt
OC
Habe gestern nachgeladen
Investor’s Watch List: Cerus Corporation (CERS)
By
Leticia Jefferson -
May 30, 2017
http://theriponadvance.com/investors-watch-list-cerus-corpor…
à bientôt
OC
Durchsuchen
Cerus Corporation (NASDAQ: CERS)
